Key highlights
- 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year
- All five biopsied lupus nephritis patients achieved DORIS remission and histologic response
- 71% of systemic sclerosis patients achieved immunomodulator-free rCRISS-50 at the one-year mark
- Management expects to report topline registrational data for myositis in the second half of 2027
- Cash reserves of $299.4 million are projected to fund operations into the first quarter of 2028
Clinical Trial Outcomes
Cabaletta Bio presented clinical results for resecabtagene autoleucel (rese-cel) at the ACR Convergence 2026 meeting. The data, derived from open-label Phase 1/2 studies, highlighted the therapy's ability to provide a reset of the immune system. In a cohort of six dermatomyositis patients, all participants maintained significant clinical improvement for at least one year while remaining off other immunomodulators. Similarly, five out of five lupus nephritis patients who underwent repeat biopsies met criteria for remission. These outcomes reinforce the potential for rese-cel to serve as a one-time, durable treatment for severe autoimmune conditions.
Strategic Significance
- Validates the weight-based dosing strategy of rese-cel across diverse autoimmune indications
- Establishes a clear regulatory path with a Biologics License Application scheduled for Q1 2028
- Provides evidence of histologic remission in lupus nephritis, a key indicator of long-term kidney health
- Demonstrates a favorable safety profile with no new safety signals across the 71-patient clinical experience
Clinical Expert Commentary
“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”
Business and Pipeline Status
Based in Philadelphia, Cabaletta Bio is a clinical-stage biotechnology firm specializing in engineered T cell therapies. The company platform utilizes a 4-1BB-containing CD19-CAR T cell construct designed to deplete B cells and allow for the regeneration of a healthy immune system. Unlike traditional CAR T therapies focused on oncology, Cabaletta targets chronic autoimmune diseases including myositis, systemic lupus erythematosus, and systemic sclerosis. The company is currently transitioning from early-phase safety studies into registrational trials, aiming to address significant unmet needs in rheumatology and neurology.
Financial Context
Cabaletta Bio reported a cash and investments balance of $299.4 million as of September 30, 2026. This capital position follows a $150 million public offering completed in May 2026, which involved the issuance of over 51 million shares. The current liquidity is expected to support the company through its major 2027 milestones, including the release of topline data for the RESET-Myositis registrational cohort. Despite the clinical progress, CABA shares have faced downward pressure, declining approximately 52% over the last quarter, with a current market capitalization of roughly $280.4 million and an RSI of 31.1.
Down 14.6% since our story on 9 Nov: $1.30 when we broke it → $1.11 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $1.48 |
|---|---|
| 20 Oct | $1.61 |
| 21 Oct | $1.54 |
| 22 Oct | $1.52 |
| 23 Oct | $1.47 |
| 26 Oct | $1.35 |
| 27 Oct | $1.46 |
| 28 Oct | $1.52 |
| 29 Oct | $1.58 |
| 30 Oct | $1.51 |
| 2 Nov | $1.43 |
| 3 Nov | $1.42 |
| 4 Nov | $1.42 |
| 5 Nov | $1.28 |
| 6 Nov | $1.30 |
| 9 Nov | $1.50 |
| 10 Nov | $1.45 |
| 11 Nov | $1.45 |
| 12 Nov | $1.33 |
| 13 Nov | $1.28 |
| 16 Nov | $1.11 |
| Date | Announcement | Amount |
|---|---|---|
| 08 Nov 2026 | Presentation of new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026Source: cabalettabio.com | – |
| 05 Nov 2026 | Third quarter 2026 financial results and business updateSource: cabalettabio.com | – |
| 13 Aug 2026 | Second quarter 2026 financial results and business updateSource: cabalettabio.com | – |
| 03 Jun 2026 | Rese-cel clinical data and autoimmune portfolio updates presented at EULAR 2026 CongressSource: cabalettabio.com | – |
| 14 May 2026 | First quarter 2026 financial results and business updateSource: cabalettabio.com | – |
| 04 May 2026 | Pricing of underwritten public offering of 51,725,000 shares of common stockSource: cabalettabio.com | $150.0 Million |
Management commentary
“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”
| Share price | $1.30 |
|---|---|
| Market cap | $280M |
| 1-month price change | -34.01% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Cabaletta Bio, Inc. announcing new Phase 1/2 clinical data for rese-cel presented at ACR Convergence 2026.
Track Cabaletta Bio, Inc. live
Get the next Cabaletta Bio, Inc. SEC filing seconds after it lands.